title: Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux® and particle therapy].
abstract: BACKGROUND
  Local control in adjuvant/definitive RT of adenoid cystic carcinoma (ACC) is largely dose-dependent leading to the establishment of particle therapy in this indication. However, even modern techniques leave space for improvement of local control by intensification of local treatment. Radiation sensitization by exploitation of high EGFR-expression in ACC with the EGFR receptor antibody cetuximab seems promising.
  
  
  METHODS
  The ACCEPT trial is a prospective, mono-centric, phase I/II trial evaluating toxicity (primary endpoint: acute and late effects) and efficacy (secondary endpoint: local control, distant control, disease-free survival, overall survival) of the combined treatment with IMRT/carbon ion boost and weekly cetuximab in 49 patients with histologically proven (≥R1-resected, inoperable or Pn+) ACC. Patients receive 18 GyE carbon ions (6 fractions) and 54 Gy IMRT (2.0 Gy/fraction) in combination with weekly cetuximab throughout radiotherapy.
  
  
  CONCLUSIONS
  The primary objective of ACCEPT is to evaluate toxicity and feasibility of cetuximab and particle therapy in adenoid cystic carcinoma.
  
  
  BACKGROUND
  Clinical Trial Identifier: NCT 01192087. EudraCT number: 2010 - 022425 - 15.
authors.affiliation: Dept. of Radiation Oncology, INF, University of Heidelberg Medical School, Heidelberg, Germany. alexandra.jensen@med.uni-heidelberg.de
authors.forename: Alexandra D
authors.initials: AD
authors.lastname: Jensen
authors.forename: Anna
authors.initials: A
authors.lastname: Nikoghosyan
authors.forename: Axel
authors.initials: A
authors.lastname: Hinke
authors.forename: Jürgen
authors.initials: J
authors.lastname: Debus
authors.forename: Marc W
authors.initials: MW
authors.lastname: Münter
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002244:Carbon; D003528:Carcinoma, Adenoid Cystic / Q000628:therapy*; D000068818:Cetuximab; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005500:Follow-Up Studies; D020869:Gene Expression Profiling; D023281:Genomics / Q000379:methods; D063193:Heavy Ion Radiotherapy; D020450:Heavy Ions / Q000009:adverse effects; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D011446:Prospective Studies; D020543:Proteome / Q000032:analysis; D040901:Proteomics / Q000379:methods; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D020543:Proteome; D002244:Carbon; D000068818:Cetuximab